Debt-to-EBITDA measures a company's ability to pay off its debt.
VistaGen Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.42 Mil. VistaGen Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $2.72 Mil. VistaGen Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2021 was $-40.88 Mil.
VistaGen Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -0.08.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for VistaGen Therapeutics's Debt-to-EBITDA or its related term are showing as below:
VTGN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.13 Med: -0.2 Max: 0
Current: -0.09
VistaGen Therapeutics Debt-to-EBITDA Historical Data
The historical data trend for VistaGen Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
VistaGen Therapeutics Annual Data
|
|
Trend |
Mar12 |
Mar13 |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
| Debt-to-EBITDA |
|
|
|
|
|
|
-0.01 |
-0.01 |
- |
-0.20 |
-0.21 |
|
VistaGen Therapeutics Quarterly Data
|
|
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
| Debt-to-EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.19 |
-0.15 |
-0.12 |
-0.07 |
-0.08 |
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Debt-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Debt-to-EBITDA falls into.
VistaGen Therapeutics Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
VistaGen Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Mar. 2021 is calculated as
VistaGen Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2021) EBITDA data.
VistaGen Therapeutics Business Description
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
| Saxe Jon S |
director |
FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
| Dotson Jerrold Duane |
officer: VP, CFO AND SECRETARY |
5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
| Singh Shawn |
director, officer: CHIEF EXECUTIVE OFFICER |
C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Snodgrass H. Ralph |
director, officer: PRES./CHIEF SCIENTIFIC OFFICER |
384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
| Smith Mark Alan |
officer: CHIEF MEDICAL OFFICER |
343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Mcpartland Mark A. |
officer: VP CORPORATE DEVELOPMENT |
C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Gin Jerry B |
director |
343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
| Underdown Brian J. |
director |
C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
| Cunningham Ann Michelle |
director |
255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
| Rice A. Franklin |
officer: VP CORPORATE DEVELOPMENT |
384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
| Bonfiglio Gregory A. |
director |
384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
| Platinum Long Term Growth Vii, Llc |
10 percent owner |
152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
| Cato Holding Co |
10 percent owner |
4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
| Cato Allen Easley |
10 percent owner |
4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
| Jones Stephanie |
director, 10 percent owner, officer: PRESIDENT |
13834 W. HOYT ROAD RATHDRUM ID 83858 |
VistaGen Therapeutics Headlines
By Seekingalpha 2021-11-10
By Seekingalpha 2021-06-29
By Seekingalpha 2021-06-30
By Seekingalpha 2021-01-24
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.01(0.48%) Volume: 715,230 2:33PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 